Literature DB >> 7531780

Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).

J M Bergelson1, J G Mohanty, R L Crowell, N F St John, D M Lublin, R W Finberg.   

Abstract

A coxsackievirus B3 (CB3) isolate adapted to growth in RD cells shows an alteration in cell tropism as a result of its capacity to bind a 70-kDa cell surface molecule expressed on these cells. We now show that this molecule is the complement regulatory protein, decay-accelerating factor (DAF) (CD55). Anti-DAF antibodies prevented CB3 attachment to the cell surface. Radiolabeled CB3 adapted to growth in RD cells bound to CHO cells transfected with human DAF, whereas CB3 (strain Nancy), the parental strain, did not bind to DAF transfectants. These results indicate that growth of CB3 in RD cells selected for a virus strain that uses DAF for cell surface attachment.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7531780      PMCID： PMC188804     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  21 in total

Review 1.  Viral receptors of the immunoglobulin superfamily.

Authors:  J M White; D R Littman
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

2.  A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses.

Authors:  K H Hsu; K Lonberg-Holm; B Alstein; R L Crowell
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

3.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Altered receptor specificity of coxsackievirus B3 after growth in rhabdomyosarcoma cells.

Authors:  K J Reagan; B Goldberg; R L Crowell
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

5.  Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade.

Authors:  R L Crowell; A K Field; W A Schleif; W L Long; R J Colonno; J E Mapoles; E A Emini
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

6.  Decay-accelerating factor in the cardiomyocytes of normal individuals and patients with myocardial infarction.

Authors:  A Zimmermann; H Gerber; V Nussenzweig; H Isliker
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

7.  Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins.

Authors:  I W Caras; M A Davitz; L Rhee; G Weddell; D W Martin; V Nussenzweig
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

8.  Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.

Authors:  M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

9.  Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

Authors:  D M Lublin; K E Coyne
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

10.  Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.

Authors:  A S Asch; T Kinoshita; E A Jaffe; V Nussenzweig
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307
View more
  88 in total

1.  Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density.

Authors:  S D Carson; J T Hobbs; S M Tracy; N M Chapman
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 2.  Xenotransplantation--2000.

Authors:  M J Goddard; J E Foweraker; J Wallwork
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

3.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Engineered BGMK cells for sensitive and rapid detection of enteroviruses.

Authors:  Yung T Huang; Paul Yam; Huimin Yan; Yan Sun
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.

Authors:  Jieyan Pan; Lili Zhang; Lindsey J Organtini; Susan Hafenstein; Jeffrey M Bergelson
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

6.  Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.

Authors:  Steven D Carson; Nora M Chapman; Susan Hafenstein; Steven Tracy
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

7.  Structure of decay-accelerating factor bound to echovirus 7: a virus-receptor complex.

Authors:  Yongning He; Feng Lin; Paul R Chipman; Carol M Bator; Timothy S Baker; Menachem Shoham; Richard J Kuhn; M Edward Medof; Michael G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

8.  Interaction with decay-accelerating factor facilitates coxsackievirus B infection of polarized epithelial cells.

Authors:  Joseph T C Shieh; Jeffrey M Bergelson
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 9.  Picornavirus uncoating.

Authors:  M S Smyth; J H Martin
Journal:  Mol Pathol       Date:  2002-08

10.  Slow Infection due to Lowering the Amount of Intact versus Empty Particles Is a Characteristic Feature of Coxsackievirus B5 Dictated by the Structural Proteins.

Authors:  Paula Turkki; Mira Laajala; Marie Stark; Helena Vandesande; Heidi Sallinen-Dal Maso; Sailee Shroff; Anna Sävneby; Ganna Galitska; A Michael Lindberg; Varpu Marjomäki
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.